Form 4: Vaxcyte Director Teri Loxam Reports Acquisition of Shares and Stock Options

Director Teri Loxam reports acquisition of common stock and stock options in Vaxcyte, Inc.

Summary

• Teri Loxam, a director of Vaxcyte, Inc., filed a Form 4 on June 10, 2024, reporting transactions in the company's securities.
• On June 6, 2024, Loxam acquired 1,550 shares of common stock underlying restricted stock units (RSUs) at a price of $0.
• These RSUs will fully vest on the earlier of June 6, 2025, or the day prior to the next annual meeting of stockholders, subject to continuous service.
• Loxam also acquired options to purchase 7,250 shares of common stock at an exercise price of $72.51 on the same date.
• These options vest monthly and will fully vest on the earlier of June 6, 2025, or the day prior to the next annual meeting of stockholders, subject to continuous service.
• Following these transactions, Loxam directly owns 7,175 shares of Vaxcyte common stock and options to purchase 7,250 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The director's acquisition of shares and options suggests confidence, but it's a routine filing.

Positives

• The acquisition of shares and options by a director signals confidence in the company's future prospects.

Future Outlook

The vesting schedules for the RSUs and stock options are tied to continued service, suggesting an ongoing commitment from the director.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors for insights into management's sentiment and potential future performance.

Comparison to Industry Standards

• Comparing Loxam's holdings and recent transactions to those of directors at similar biotech companies like Moderna or BioNTech would provide a benchmark for assessing the magnitude of her investment.
• For example, if directors at comparable companies have significantly larger holdings relative to their compensation, it might suggest a stronger alignment of interests with shareholders.
• Similarly, analyzing the vesting schedules of equity grants at peer companies can reveal whether Vaxcyte's practices are standard or more aggressive in incentivizing long-term performance.

Stakeholder Impact

• The reported transactions provide shareholders with insight into the director's investment in the company.
• The vesting schedules for the RSUs and stock options incentivize the director to contribute to the company's long-term success.

Key Dates